Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › WVE

Wave Life Sciences

WVE Rare disease Lead: Phase 2 9 Biotech Distilled articles ↓ 39 filings & releases ↓ Cash $197M (Sep 30, 2026) ↓ 9 verdicts ↓ 8 timing quotes ↓
MetabolicNeurologyRespiratory Nucleic Acid

Market cap $665M 197.2M shares (10-Q, Oct 21, 2026) × $3.37 close Nov 6, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. WVE-N531 NDA filing2026WVE-N531 NDA filing, 2026, notable
  2. Company guidance updatefall of 2026Company guidance update, fall of 2026, routine
  3. AATD program Ph1 readout4Q 2026AATD program Ph1 readout, 4Q 2026, material
  4. WVE-008 filing4Q 2026WVE-008 filing, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

PRISM · GSK

Proprietary RNA medicines discovery and drug development platform combining stereochemistry-controlled oligonucleotide chemistry, multiple RNA-targeting modalities (RNAi/SpiNA, RNA editing/AIMers, antisense, splicing, bifunctional), and GalNAc or free-uptake delivery. Enables development of stereopure oligonucleotides for rare and common diseases including hepatic/metabolic, neuromuscular, and neurodegenerative diseases.

PRISM

RNA medicines platform combining multiple RNA medicine modalities (RNAi/SpiNA, RNA editing/AIMers, antisense silencing, splicing), chemistry innovation, and human genetics insights; addresses rare and common disorders including hepatic, metabolic, neurodegenerative, and neuromuscular diseases; enables GalNAc-conjugated and free-uptake delivery without complex delivery vehicles.

SpiNA

Stereopure interfering Nucleic Acid — proprietary RNAi chemistry platform delivering improvements in potency, duration of activity, and Ago2 loading; focus areas include obesity, liver disease, and other extra-hepatic indications

AIMer

RNA editing platform using proprietary chemistry to achieve site-directed A-to-I RNA editing; focus areas include alpha-1 antitrypsin deficiency and liver disease

GSK Collaboration · GlaxoSmithKline

Target validation and candidate development collaboration with GlaxoSmithKline using Wave's PRISM chemistry for multiple GalNAc-siRNA programs targeting hepatic diseases; GSK prepays all costs and exercises selection rights upon candidate transition.

Capital (as filed)

Cash
$197M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$233M Sep 30, 2026
Long-term investments
$263K Sep 30, 2026
Operating cash flow
−$60.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$431M cash, runway 3Q 2028 per the update of Oct 27, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Wave Life Sciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-03-03 Buy speculative Wave Life Sciences (WVE) - Scientific Deep Dive for Lead and Pipeline Products Wave's stereopure RNA platform with GalNAc delivery is scientifically compelling and well-capitalized, warranting a starter position ahead of major 2026 clinical readouts in obesity and AATD.
  2. 2026-03-27 Buy core UPDATE: Wave Life Sciences (WVE) - The Receipts Are In on WVE-007... The retail sell-off on WVE-007 data fundamentally misreads the mechanism; the visceral fat and lean mass data are strong, making the post-crash price a compelling entry ahead of Phase 2a and WVE-006 AATD data.
  3. 2026-04-05 Buy core UPDATE: Wave Life Sciences (WVE) - The Smart Money Just Faded the Retail Panic RA Capital's $54.5M open-market accumulation following the data drop validates the buy-the-dip thesis and signals high institutional conviction ahead of the May WVE-006 AATD readout.
  4. 2026-04-17 Buy core UPDATE: Wave Life Sciences (WVE) - Redomiciling to Delaware The redomiciliation to Delaware is a clean administrative move that reduces M&A friction; the strong conviction buy stance is unchanged ahead of the May ATS AATD readout.
  5. 2026-04-30 Buy core UPDATE: Wave Life Sciences (WVE) - The Clock is Set for May 18 The May 18 ATS readout is now a hard binary event with a locked date; the pre-event price drift looks like routine compression rather than smart-money exit, and the asymmetry favors holding through the AATD data.
  6. 2026-05-18 Buy core UPDATE: Wave Life Sciences (WVE) - The MZ Phenotype Is Real, And So Is the Dynamic Response WVE-006 ATS data cleared every bar set three weeks prior — MZ-phenotype shift replicated, dynamic AAT response now reproducible, safety clean — materially de-risking the AATD platform thesis ahead of mid-2026 FDA accelerated-approval feedback.
  7. 2026-07-30 Buy core UPDATE: Wave Life Sciences (WVE) - The FDA Meeting Has a Season, and the CEO Has a Plan The FDA accelerated-approval meeting is now scheduled for end of summer, the clinical case is intact, but the CEO's large 10b5-1 sale plan and accelerating burn rate temper conviction, warranting a hold rather than adding into the catalyst gap.
  8. 2026-10-01 Hold UPDATE: Wave Life Sciences (WVE) - The FDA Said "Yes, But Run Another Trial" FDA requires a new two-year registrational trial for WVE-006 accelerated approval, pushing the timeline past the current cash runway and reopening the dilution risk, so the call is downgraded from Buy to Hold pending trial design and funding clarity.
  9. 2026-10-28 Hold UPDATE: Wave Life Sciences (WVE) - The Insider Overhang That Wasn't The CEO's 2.9M-share sale plan was cancelled with zero shares sold, removing a key bear argument, but the funding gap for the WVE-006 registrational trial remains unresolved, keeping the stance at Hold.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (8 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (39)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

30 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)